Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.

Ayumi YoshifujiMasataro TodaEmi OyamaTetsuo NakayamaSetsuko Mise-OmataKan KikuchiMamoru YoshizawaNaohiko KatoHaruki WakaiKiyoto KoibuchiKohkichi MorimotoYoshifumi UwaminoHo NamkoongAyako ShibataKaoru WakabayashiMotoko FujinoMotoaki KomatsuNaoki MochizukiNorihiko KondoAkihiko YoshimuraNaoki HasegawaMunekazu Ryuzaki

Published in: Clinical and experimental nephrology (2024)

HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.

Keyphrases

end stage renal disease
immune response
chronic kidney disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
dendritic cells